Schemionek, M
Herrmann, O
Reher, M M
Chatain, N
Schubert, C
Costa, I G
Hänzelmann, S
Gusmao, E G
Kintsler, S
Braunschweig, T
Hamilton, A
Helgason, G V
Copland, M
Schwab, A
Müller-Tidow, C
Li, S
Holyoake, T L
Brümmendorf, T H
Koschmieder, S
Article History
Received: 23 July 2015
Revised: 23 October 2015
Accepted: 16 November 2015
First Online: 1 December 2015
Competing interests
: SK has received research funding from Novartis and the Novartis Foundation, provided consultancy for and participated in advisory boards for Ariad, Bristol-Myers Squibb, Novartis and Pfizer, and has received honoraria and travel grants from Ariad, Bristol-Myers Squibb, Novartis and Pfizer. MC has received research funding from Novartis and Bristol-Myers Squibb, is an advisory board member for Bristol-Myers Squibb, Novartis, Ariad and Pfizer, has received travel reimbursement from Bristol-Myers Squibb and Novartis and has received honoraria from Bristol-Myers Squibb, Novartis, Ariad and Pfizer. All other authors declare no conflict of interest.